Sustained good momentum, but with some caution
18/11/22 -"After another quarterly performance beat in Q3, Novo remains on track to sustain its exceptional operating momentum. Besides our medium-term estimates resetting marginally higher, the DCF and NAV ..."
Pages
73
Language
English
Published on
18/11/22
You may also be interested by these reports :
07/10/26
Our estimates are already at the higher end, with our target price significantly benefitting from increased NAV and DCF estimates, as well as a ...
30/09/26
Lundbeck, as per Bloomberg, is pursuing endocrine- and neurology-focused Xeris Biopharma, whose market cap is c.28% of that of Lundbeck. Considering ...
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...